Evaluation of Pegylated Liposomal Doxorubicin in the Treatment Of Both Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer

• Main Authors: Hao Lin (Author), Chih-Wen Tseng (Author), Hung-Yaw Chang (Author), Hsien-Ming Lu (Author), Yu-Che Ou (Author), Chan-Chao Changchien (Author)
• Format: Book
• Published: Elsevier, 2004-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Pegylated liposomal doxorubicin (PLD) is a stealth liposomal form of doxorubicin that has been approved for the treatment of patients with relapsed ovarian cancer. Previous studies have shown a response rate of about 25% in patients who had treatment failure with prior platinum- and/or pa...